August 26, 2016 09:26 AM EDT
R&D

Amid lay­off fears, As­traZeneca stakes a ‘For Sale’ sign on US cam­pus

John Carroll

Editor & Founder

Af­ter culling work­ers in Boston and Mary­land, As­traZeneca is con­sid­er­ing its op­tions for its US head­quar­ters cam­pus in Delaware. The lo­cal pa­pers have been re­port­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times